Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) EBIT (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of EBIT data on record, last reported at -$52.6 million in Q3 2025.

  • For Q3 2025, EBIT fell 28.29% year-over-year to -$52.6 million; the TTM value through Sep 2025 reached -$200.7 million, down 176.29%, while the annual FY2024 figure was -$163.9 million, 341.19% down from the prior year.
  • EBIT reached -$52.6 million in Q3 2025 per ZBIO's latest filing, up from -$55.2 million in the prior quarter.
  • Across five years, EBIT topped out at $35.6 million in Q3 2023 and bottomed at -$55.6 million in Q4 2024.
  • Average EBIT over 3 years is -$34.2 million, with a median of -$40.3 million recorded in 2024.
  • Peak YoY movement for EBIT: tumbled 215.05% in 2024, then dropped 28.29% in 2025.
  • A 3-year view of EBIT shows it stood at $35.6 million in 2023, then plummeted by 256.14% to -$55.6 million in 2024, then grew by 5.47% to -$52.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$52.6 million in Q3 2025, -$55.2 million in Q2 2025, and -$37.3 million in Q1 2025.